Tolerability, immunogenicity and persistence of immune response to tetanus, diphtheria and pertussis (Tdap) vaccine in adolescents infected by the Human Immunodeficiency Virus (HIV)

• Grant number: 13/21853-1
• Support Opportunities: Regular Research Grants
• Start date: November 01, 2014
• End date: January 31, 2017
• Field of knowledge: Health Sciences - Medicine - Maternal and Child Health
• Principal Investigator: Maria Isabel de Moraes Pinto
• Grantee: Maria Isabel de Moraes Pinto
• Host Institution: Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil
• Associated researchers: Aida de Fatima Thome Barbosa Gouvea ; Fernanda Garcia Spina ; Maria Teresa de Sande e Lemos Ramos Ascensão Terreri ; Regina Célia de Menezes Succi

Abstract

Despite the impressive decay in morbidity and mortality among HIV-infected children and adolescents due to the use of antiretroviral therapy, they are still more susceptible to infectious diseases and have a reduced response to vaccination. Tetanus-diphtheria (Td) vaccine and, when available, tetanus, diphtheria and acellular pertussis (Tdap) are recommended to adolescents at the age of 15. However, not much is known about the immune response to vaccination among HIV-infected adolescents. In the present study, we aim to investigate the cellular and humoral immune response to Tdap in HIV-infected adolescents. HIV-infected adolescents (n=30) and 40 age and gender-matched healthy controls (n=40) will be prospectively followed up.Those with a complete tetanus, diphtheria and whole cell pertussis vaccination scheme with at least 3 vaccine doses (the last one at least 3 years before and in the previous 11 years) will be recruited. Gestation will be considered as an exclusion criterion. Those who agree to participate will receive one Tdap vaccine dose. Samples will be collected on day zero (urine for pregnancy test and blood for complete blood count, HIV viral load, serum antibodies to tetanus, diphtheria and pertussis toxin, cellular immune response to tetanus toxoid and lymphocyte immunophenotyping). On day 7, cellular immune response to tetanus toxoid and humoral immune response to the 3 antigens will be assessed; on day 28, HIV viral load, cellular immune response to tetanus toxoid and humoral immune response to the 3 antigens. After 6,12, 24 e 36 months, humoral immune response to the 3 antigens will be assessed. Results from this project will provide information on the maintenance of immune response to DTP administered during childhood. It will also allow evaluation of both cellular and humoral immune response to Tdpa and of the persistence of humoral immune response in the following 36 months. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

CANO MUNHOZ, LUIZ GUSTAVO; SPINA, FERNANDA GARCIA; MACHADO, DAISY MARIA; GOUVEA, AIDA; DE MENEZES SUCCI, REGINA CELIA; DIAZ, RICARDO SOBHIE; DE MORAES-PINTO, MARIA ISABEL. Prolonged Antiretroviral Therapy in Adolescents With Vertical HIV Infection Leads to Different Cytokine Profiles Depending on Viremia Persistence. PEDIATRIC INFECTIOUS DISEASE JOURNAL, v. 38, n. 11, p. 1115-1120, NOV 2019. (13/21853-1)